Stock DCPH DECIPHERA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 01:53:25 2024-04-25 pm EDT 		5-day change 1st Jan Change
14.37 USD -1.71% Intraday chart for Deciphera Pharmaceuticals, Inc. +1.12% -10.79%
Mar. 13 Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM
Feb. 06 Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises MT

Business Summary

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

Number of employees: 355

Sales per Business

USD in Million2022Weight2023Weight Delta
Switch Control Kinase Inhibitor Platform
100.0 %
126 100.0 % 159 100.0 % +26.75%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
76.4 %
97 77.5 % 122 76.4 % +25.03%
Rest of World
12.3 %
14 11.1 % 20 12.3 % +39.91%
Germany
11.3 %
14 11.4 % 18 11.3 % +25.58%

Managers

Managers TitleAgeSince
Steven Hoerter CEO
 Chief Executive Officer 53 18-05-16
Tucker Kelly DFI
 Director of Finance/CFO 53 15-01-31
Kevin Brodbeck CTO
 Chief Tech/Sci/R&D Officer - 22-12-31
Rodrigo Ruiz Soto CTO
 Chief Tech/Sci/R&D Officer - 16-12-31
Dashyant Dhanak CTO
 Chief Tech/Sci/R&D Officer 63 23-09-04
Matthew Sherman CTO
 Chief Tech/Sci/R&D Officer 68 19-10-01
Lisa Amaya Price HRO
 Human Resources Officer - 21-12-31
Kelley Dealhoy PRN
 Corporate Officer/Principal - 22-06-15
Jama Pitman PRN
 Corporate Officer/Principal 45 14-12-31
Daniel Martin PRN
 Corporate Officer/Principal 49 18-09-17

Members of the board

Members of the board TitleAgeSince
Patricia Allen BRD
 Director/Board Member 62 16-08-31
Edward Benz BRD
 Director/Board Member 78 19-06-30
Ron Squarer CHM
 Chairman 57 19-12-03
John R. Martin BRD
 Director/Board Member 63 15-01-31
James Bristol BRD
 Director/Board Member 77 07-07-31
Susan Kelley BRD
 Director/Board Member 69 19-07-07
Steven Hoerter CEO
 Chief Executive Officer 53 18-05-16
Dennis Walsh BRD
 Director/Board Member 56 15-01-31
Franklin Friedman BRD
 Director/Board Member 66 19-10-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 80,800,062 56,163,557 ( 69.51 %) 0 69.51 %

Shareholders

NameEquities%Valuation
Brightstar Associates LLC
28.54 %
23,059,708 28.54 % 363 M $
Deerfield Management Co. LP (Private Equity)
7.163 %
5,788,024 7.163 % 91 M $
BlackRock Advisors LLC
6.889 %
5,566,249 6.889 % 88 M $
Armistice Capital LLC
6.436 %
5,200,000 6.436 % 82 M $
Redmile Group LLC
5.942 %
4,801,540 5.942 % 76 M $
Vanguard Fiduciary Trust Co.
5.448 %
4,401,636 5.448 % 69 M $
STATE STREET CORPORATION
3.058 %
2,470,813 3.058 % 39 M $
Morgan Stanley Investment Management, Inc.
2.867 %
2,316,433 2.867 % 36 M $
Goldman Sachs Asset Management LP
2.856 %
2,307,475 2.856 % 36 M $
POLAR CAPITAL HOLDINGS PLC
2.290 %
1,850,000 2.290 % 29 M $

Company contact information

Deciphera Pharmaceuticals, Inc.

200 Smith Street

02451, Waltham

+781 209 6400

http://www.deciphera.com
address Deciphera Pharmaceuticals, Inc.(DCPH)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Deciphera Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
14.62 USD
Average target price
24.2 USD
Spread / Average Target
+65.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DECIPHERA PHARMACEUTICALS, INC. Stock Deciphera Pharmaceuticals, Inc.
-9.36% 1.2B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+1.86% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-8.49% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DCPH Stock
  4. Company Deciphera Pharmaceuticals, Inc.